Uptake of pertussis immunization in pregnancy and determinants of vaccination in Toronto, Canada.
Immunization in pregnancy
Pertussis
Vaccine preventable diseases
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
13 11 2023
13 11 2023
Historique:
received:
28
06
2023
revised:
29
09
2023
accepted:
10
10
2023
medline:
3
11
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
ppublish
Résumé
Pertussis causes significant morbidity and mortality in infants aged <6 months. Maternal pertussis vaccination during pregnancy has been recommended in Canada since 2018 to reduce these negative outcomes. In the absence of routine immunization coverage data, our objective was to evaluate uptake in Toronto, Canada. We recruited mother-infant pairs at The Hospital for Sick Children, Toronto, between 2018 and 2020. We performed logistic regression to examine associations between demographics and self-reported pertussis vaccination. 76/243 mothers (31.3 %) reported receiving pertussis vaccination during their most recent pregnancy. Odds of receiving vaccination more than doubled with each 1-year increase in year of pregnancy (aOR: 2.2; 95 % CI: 1.3, 3.6; p < 0.01) and among those born in Canada as compared to those not (aOR: 2.0; 95 % CI: 1.1, 3.6; p = 0.02) CONCLUSION: Uptake of pertussis vaccination during pregnancy in Ontario has increased in recent years, however coverage remains lower than desirable.
Identifiants
pubmed: 37845156
pii: S0264-410X(23)01192-1
doi: 10.1016/j.vaccine.2023.10.020
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6895-6898Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Scott Halperin reports financial support was provided by Sanofi Pastuer. Scott Halperin reports financial support was provided by GlaxoSmithKline. Todd Hatchette reports financial support was provided by GlaxoSmithKline. Todd Hatchette reports financial support was provided by Pfizer. Shelly Bolotin is the Director of the Centre for Vaccine Preventable Diseases (CVPD) at the University of Toronto. The CVPD receives operational support from a mix of funding sources, including through donations from pharmaceutical companies. A robust set of governance practices are in place to safeguard the academic freedom of the CVPD.